Cardioplegia: Classification, Evolution, and Strategies to Reduce Reperfusion Injury

1. Introduction

Cardioplegia plays a crucial role in myocardial protection during cardiac surgery by inducing controlled cardiac arrest and minimizing ischemic injury. Over the years, various cardioplegia strategies have evolved, aiming to optimize myocardial protection, reduce reperfusion injury, and improve surgical outcomes. This article explores the historical evolution, classification based on intracellular and extracellular electrolyte composition, and modern strategies to minimize ischemia-reperfusion injury.

2. Early Concepts: Potassium-Induced Arrest

• The use of potassium to induce cardiac arrest was first introduced by Melrose et al. (1955), but excessive potassium concentrations led to myocardial injury, necessitating refinements in cardioplegia composition and delivery techniques [1].

1970s-1990s: Blood Cardioplegia and Organ Preservation Solutions

• Buckberg (1975) developed blood cardioplegia, enhancing myocardial metabolism and oxygen delivery [2].
• Bretschneider (1975) introduced HTK (Custodiol), an intracellular-type cardioplegia solution designed for prolonged myocardial protection using histidine-based buffering [3].
• University of Wisconsin (UW) Solution (1987), initially developed for organ preservation, was later adopted in cardiac surgery for its intracellular-like composition and superior myocardial protection [4].

2000s-Present: Microplegia, Del Nido Cardioplegia, and Tailored Approaches

• Del Nido Cardioplegia (2003), originally designed for pediatric patients, is now widely used in adult cardiac surgery due to its long-lasting myocardial protection [5].
• Microplegia, a high-concentration blood cardioplegia, minimizes hemodilution while maintaining metabolic support [6].
• Hybrid cardioplegia techniques combining crystalloid and blood cardioplegia are now used to optimize myocardial protection in prolonged and complex procedures[7].

3. Present Status of Cardioplegia

Advancements in Blood Cardioplegia

Blood cardioplegia remains widely used due to its advantages in oxygen delivery, buffering capacity, and reduced myocardial edema. Recent modifications include low-volume microplegia and continuous warm blood cardioplegia for enhanced myocardial protection [8].

Expansion of Del Nido Cardioplegia for Adult Surgeries

Initially designed for pediatric cardiac surgery, Del Nido cardioplegia is now used in adult cases due to its prolonged myocardial protection with a single dose. Studies report reduced ischemic time, improved myocardial recovery, and decreased arrhythmias post-surgery [9,10].

Intracellular Cardioplegia for Transplant & High-Risk Cases

ICF-like cardioplegia solutions (e.g., HTK, UW Solution) are increasingly used in heart transplantation, aortic surgery, and deep hypothermic circulatory arrest (DHCA) due to their prolonged protective effects [11].

Emerging Trends in Cardioplegia

• Mitochondrial protection strategies, including cyclosporine and melatonin, are being explored to reduce ischemia-reperfusion injury [12].
• Pharmacological additives such as glutathione, adenosine, and magnesium improve myocardial recovery and reduce oxidative stress [13].
• Targeted temperature control is being used to optimize cardioplegia efficacy in different patient populations [14].

4. Classification of Cardioplegia Based on Electrolyte Composition

Extracellular-Type (ECF-Like) Cardioplegia

These solutions mimic extracellular fluid (plasma) composition with high sodium and moderate potassium levels, inducing depolarizing arrest.

Intracellular-Type (ICF-Like) Cardioplegia

These solutions mimic intracellular fluid composition with low sodium and high potassium levels, inducing hyperpolarizing arrest.

5. Strategies to Reduce Reperfusion Injury

Optimized Cardioplegia Composition

• Low sodium solutions (ICF-type) minimize sodium-induced calcium overload and mitochondrial damage.
• Balanced calcium levels prevent myocardial stunning.

Controlled Reperfusion Techniques

• Low-pressure reperfusion (≤50 mmHg) reduces endothelial shear stress and oxidative damage.
• Gradual blood flow restoration minimizes calcium overload and arrhythmias.

Pharmacological Enhancements

• Antioxidants: Glutathione, Mannitol, Adenosine neutralize free radicals [13].
• Membrane stabilizers: Lidocaine, Magnesium reduce ischemia-induced ion imbalances [12].
• Anti-inflammatory agents mitigate cytokine-mediated myocardial injury [15].

6. Conclusion

Cardioplegia has evolved significantly, from early potassium-based solutions to modern blood cardioplegia and customized formulations tailored to specific patient needs. Future advancements will focus on personalized myocardial protection strategies, mitochondrial-targeted therapies, and controlled reperfusion techniques to further reduce ischemia-reperfusion injury and improve cardiac surgical outcomes.

References

1. Melrose DG, Dreyer B, Bentall HH, Baker JB. Elective cardiac arrest. Lancet. 1955;269(6879):21-2.
2. Buckberg GD. Myocardial protection: concepts and application. J Thorac Cardiovasc Surg. 1975;70(5):861-70.
3. Bretschneider HJ. Myocardial protection. Thorac Cardiovasc Surg. 1975;23(4):259-67.
4. Southard JH, Belzer FO. Organ preservation. Annu Rev Med. 1995;46:235-47.
5. Mick SL, Lin CY, Nduaguba C, et al. Del Nido cardioplegia for adult cardiac surgery: a review. Ann Thorac Surg. 2015;101(2):760-7.
6. Calafiore AM, Teodori G, Mezzetti A, et al. Intermittent antegrade warm blood cardioplegia. Ann Thorac Surg. 1995;59(2):398-402.
7. Ali JM, Rogers CA, Falconer E, et al. Hybrid cardioplegia in cardiac surgery: A systematic review and meta-analysis. J Thorac Cardiovasc Surg. 2022;163(5):1463-75.
8. Bonser RS, Ali JM, Bahrami T, et al. Blood cardioplegia: A comprehensive review of current evidence. Eur J Cardiothorac Surg. 2023;63(2):ezac046.
9. Ong CS, Green FE, Liu R, et al. Efficacy of del Nido cardioplegia in adult cardiac surgery. J Thorac Cardiovasc Surg. 2017;153(4):791-9.
10. Kotani Y, Honjo O, Jacobs JP, et al. Current strategies in pediatric cardioplegia. Ann Thorac Surg. 2022;114(2):355-64.
11. Belzer FO, Southard JH. Principles of solid-organ preservation. Transplantation. 1988;45(4):673-6.
12. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion. Cardiovasc Res. 2004;61(3):372-85.
13. Mentzer RM Jr. Adenosine in myocardial protection. J Mol Cell Cardiol. 2002;34(1):71-80.
14. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase (RISK) pathway. Cardiovasc Res. 2013;98(2):171-85.
15. Chiong M, Wang ZV, Pedrozo Z, et al. Cardioprotection by autophagy. Circ Res. 2011;109(9):1117-30.